Clinical Trial Update: TMC114-C201: A Study to Determine the Antiviral Activity of TMC114 in Patients With Multiple Protease Inhibitor (PI) Resistant Human Immunodeficiency Virus (HIV) Strains [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the antiviral activity of TMC114 (darunavir) in HIV patients with multiple protease inhibitor–resistant strains; the trial status is co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• PREZISTA (darunavir)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV Infections | Phase 2 | Status: COMPLETED